Last 47 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.43 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.15 | 0.36 | 0.28 | 0.29 | 0.18 | 0.28 | 0.22 | 0.27 | 0.19 | 0.16 | 0.73 | 0.77 | 0.76 |
| — | +29.8% | +28.5% | +9.4% | -4.2% | +76.1% | -69.6% | -65.5% | -75.1% | -73.5% | -26.4% | -32.2% | -68.6% | |
| P/B Ratio | 0.34 | 1.82 | 1.69 | 1.15 | 0.62 | 0.81 | 0.59 | 0.73 | 0.42 | 0.29 | 1.40 | 1.46 | 1.15 |
| — | +124.7% | +184.3% | +58.9% | +45.5% | +174.8% | -57.8% | -50.2% | -63.0% | -76.5% | -25.3% | -35.9% | -55.2% | |
| P/FCF | — | — | — | — | 1.21 | 3.00 | 2.42 | — | 4.19 | 0.87 | — | — | — |
| — | — | — | — | -71.2% | +243.3% | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Sonoma Pharmaceuticals, Inc.'s operating margin was -15.6% in Q3 2026, down 9.6 pp QoQ and up 13.3 pp YoY. Gross margin expanded 6.5% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.2% | 37.9% | 37.8% | 36.5% | 40.7% | 35.6% | 38.0% | 38.5% | 31.7% | 46.5% | 36.3% | 35.1% | 28.7% |
| — | +6.5% | -0.5% | -5.3% | +28.3% | -23.4% | +4.9% | +9.6% | +10.7% | +64.8% | -21.4% | -15.0% | +586.2% | |
| Operating Margin | -26.0% | -15.6% | -6.0% | -27.3% | -17.5% | -28.9% | -23.7% | -34.6% | -41.0% | -26.9% | -44.2% | -36.2% | -38.1% |
| — | +46.1% | +74.7% | +21.2% | +57.3% | -7.6% | +46.3% | +4.4% | -7.7% | +56.8% | -101.6% | -68.6% | +71.4% | |
| Net Margin | -24.2% | -18.8% | -9.5% | -30.9% | -20.7% | -26.0% | -17.0% | -33.7% | -31.0% | -27.6% | -54.3% | -41.4% | -43.4% |
| — | +27.7% | +44.1% | +8.3% | +33.4% | +5.6% | +68.6% | +18.5% | +28.5% | +58.1% | -78.0% | -85.8% | +66.1% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -65.5% | -22.7% | -13.6% | -29.3% | -16.7% | -18.2% | -11.8% | -20.6% | -16.6% | -14.0% | -23.0% | -18.6% | -19.3% |
| — | -25.0% | -15.3% | -42.5% | -0.5% | -29.6% | +48.6% | -10.4% | +13.9% | +54.6% | -69.2% | -75.0% | +34.8% | |
| ROA | -24.3% | -6.0% | -3.8% | -8.8% | -5.7% | -6.8% | -4.5% | -8.0% | -7.3% | -6.1% | -10.1% | -8.8% | -8.7% |
| — | +12.2% | +15.8% | -9.1% | +22.0% | -10.7% | +55.6% | +8.9% | +16.2% | +54.3% | -58.7% | -79.2% | +43.7% | |
| ROIC | -188.1% | -36.2% | -20.9% | -351.0% | — | -121.7% | -29.5% | -27.4% | -25.5% | -14.5% | -21.5% | -19.9% | -20.4% |
| — | +70.3% | +29.0% | -1181.2% | — | -739.1% | -36.9% | -37.8% | -24.8% | +58.6% | -52.6% | +7.1% | +71.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 13.9% YoY to 2.88x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.19 | 0.14 | 0.17 | 0.07 | 0.02 | 0.05 | 0.08 | 0.10 | 0.06 | 0.09 | 0.09 | 0.11 |
| — | +681.1% | +209.9% | +97.1% | -30.2% | -57.5% | -50.4% | -6.7% | -6.9% | -34.2% | -16.6% | -24.4% | -32.3% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.09 | 2.88 | 2.89 | 2.70 | 3.09 | 3.34 | 3.69 | 3.18 | 3.37 | 4.07 | 3.56 | 3.36 | 3.71 |
| — | -13.9% | -21.7% | -15.0% | -8.5% | -17.8% | +3.9% | -5.4% | -9.1% | +42.4% | +1.2% | +10.1% | +31.5% | |
| Quick Ratio | 2.38 | 2.00 | 2.05 | 1.92 | 2.38 | 2.49 | 2.84 | 2.47 | 2.64 | 3.11 | 2.78 | 2.69 | 2.94 |
| — | -19.7% | -27.7% | -22.3% | -10.1% | -19.7% | +2.0% | -8.0% | -10.2% | +45.7% | +4.6% | +8.4% | +24.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying SNOA stock.
Sonoma Pharmaceuticals, Inc.'s current P/E is -0.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Sonoma Pharmaceuticals, Inc.'s current operating margin is -26.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Sonoma Pharmaceuticals, Inc.'s business trajectory between earnings reports.